NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free SPRY Stock Alerts $8.93 +0.10 (+1.13%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$8.82▼$9.0550-Day Range$8.09▼$10.2252-Week Range$2.55▼$11.27Volume230,171 shsAverage Volume413,190 shsMarket Capitalization$865.23 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ARS Pharmaceuticals alerts: Email Address ARS Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.2% Upside$18.50 Price TargetShort InterestBearish15.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.08Based on 6 Articles This WeekInsider TradingAcquiring Shares$8.92 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.72) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 starsMedical Sector447th out of 920 stocksPharmaceutical Preparations Industry199th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.81% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 4.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRY. Previous Next 1.1 News and Social Media Coverage News SentimentARS Pharmaceuticals has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have bought 38.22% more of their company's stock than they have sold. Specifically, they have bought $8,917,946.00 in company stock and sold $6,452,141.00 in company stock.Percentage Held by Insiders40.10% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.72) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ARS Pharmaceuticals Stock (NASDAQ:SPRY)ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More SPRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRY Stock News HeadlinesMay 17, 2024 | insidertrades.comRichard E. Lowenthal Sells 5,147 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMay 10, 2024 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of StockMay 18, 2024 | americanbankingnews.comSarina Tanimoto Sells 89,096 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMay 13, 2024 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Forecasted to Earn FY2027 Earnings of $0.60 Per ShareMay 13, 2024 | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...May 11, 2024 | finance.yahoo.comARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)May 9, 2024 | investorplace.comSPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024May 9, 2024 | globenewswire.comARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | nasdaq.comARS Pharmaceuticals, Inc. Common Stock (SPRY) Insider ActivityApril 30, 2024 | finance.yahoo.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 30, 2024 | globenewswire.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 26, 2024 | msn.comInsider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679KApril 19, 2024 | investing.comArs Pharmaceuticals CEO sells over $928k in company stockApril 12, 2024 | investing.comArs Pharmaceuticals CEO sells shares worth over $927kApril 12, 2024 | investing.comArs pharmaceuticals exec sells shares worth over $927kApril 3, 2024 | markets.businessinsider.comARS Pharma Submits Addl. Data In Response To FDA's CRL For NeffyApril 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn SituationApril 3, 2024 | globenewswire.comARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)March 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 25, 2024 | markets.businessinsider.comBuy Rating on ARS Pharmaceuticals Amid Strong neffy Approval Prospects and Indication ExpansionMarch 21, 2024 | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial ResultsMarch 21, 2024 | globenewswire.comARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayMarch 6, 2024 | realmoney.thestreet.comARS Pharmaceuticals just upgraded at Leerink, here's whyMarch 6, 2024 | globenewswire.comARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024See More Headlines Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/23/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SPRY CUSIPN/A CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$19.00 Low Stock Price Target$18.00 Potential Upside/Downside+107.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-496,960.06% Return on Equity-21.14% Return on Assets-20.53% Debt Debt-to-Equity RatioN/A Current Ratio60.90 Quick Ratio60.90 Sales & Book Value Annual Sales$10,000.00 Price / Sales86,527.24 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book3.87Miscellaneous Outstanding Shares96,895,000Free Float58,040,000Market Cap$865.27 million OptionableOptionable Beta0.88 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Richard Lowenthal M.B.A. (Age 58)M.S., MSMSEL, Founder, President, CEO & Director Comp: $2.75MDr. Sarina Tanimoto M.B.A. (Age 55)M.D., Co-Founder & Chief Medical Officer Comp: $2.47MMr. Alexander A. Fitzpatrick Esq. (Age 57)Chief Legal Officer & Secretary Comp: $677.14kDr. Robert Bell Ph.D.Co-Founder & Chief Science OfficerMs. Kathleen D. Scott CPAChief Financial OfficerMr. Brian T. Dorsey M.S. (Age 55)Chief Operations Officer Mr. Daniel RelovskySenior Vice President of MarketingMr. Harris Kaplan M.B.A. (Age 72)Executive Vice President of Commercial Strategy Mr. Eric Karas (Age 51)Chief Commercial Officer Comp: $618.61kMr. Justin Chakma (Age 34)Chief Business Officer & Secretary More ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAPliant TherapeuticsNASDAQ:PLRX89bioNASDAQ:ETNBZentalis PharmaceuticalsNASDAQ:ZNTLTango TherapeuticsNASDAQ:TNGXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 20,201 shares on 5/20/2024Ownership: 0.021%RA Capital Management L.P.Bought 1,401,299 shares on 5/17/2024Ownership: 11.210%Sarina TanimotoSold 89,096 sharesTotal: $807,209.76 ($9.06/share)Levin Capital Strategies L.P.Bought 3,000 shares on 5/16/2024Ownership: 0.057%California State Teachers Retirement SystemSold 1,145 shares on 5/16/2024Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions SPRY Stock Analysis - Frequently Asked Questions Should I buy or sell ARS Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares. View SPRY analyst ratings or view top-rated stocks. What is ARS Pharmaceuticals' stock price target for 2024? 4 analysts have issued 12 month price objectives for ARS Pharmaceuticals' shares. Their SPRY share price targets range from $18.00 to $19.00. On average, they predict the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 107.2% from the stock's current price. View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts. How have SPRY shares performed in 2024? ARS Pharmaceuticals' stock was trading at $5.48 on January 1st, 2024. Since then, SPRY shares have increased by 63.0% and is now trading at $8.93. View the best growth stocks for 2024 here. When is ARS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SPRY earnings forecast. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its earnings results on Thursday, May, 9th. The company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). Who are ARS Pharmaceuticals' major shareholders? ARS Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (11.21%), Vanguard Group Inc. (2.98%), Jacobs Levy Equity Management Inc. (0.29%), ClariVest Asset Management LLC (0.28%), GSA Capital Partners LLP (0.13%) and AWM Investment Company Inc. (0.10%). Insiders that own company stock include Alexander A Fitzpatrick, Kathleen D Scott, Laura Shawver, Ra Capital Management, LP, Richard E Lowenthal and Sarina Tanimoto. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRY) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeBitcoin’s Biggest Year YetParadigm PressDividend-like income from non-dividend stocksUnstoppable Prosperity[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaAlex’s “Next Magnificent Seven” stocksThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
